TRxADE HEALTH, Inc. (MEDS)
USD 7.59
(4.55%)
USD 7.59
(4.55%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -13.72 Million USD | -143.92% |
| 2022 | -1.84 Million USD | 50.72% |
| 2021 | -5.15 Million USD | -207.08% |
| 2020 | -2.5 Million USD | -354.06% |
| 2019 | 660.55 Thousand USD | 170.88% |
| 2018 | 96.65 Thousand USD | -66.62% |
| 2017 | 288.98 Thousand USD | 174.23% |
| 2016 | -984.03 Thousand USD | -0.08% |
| 2015 | -133.26 Thousand USD | 31.08% |
| 2014 | -2 Million USD | 31.41% |
| 2013 | -2.08 Million USD | -1304.58% |
| 2012 | -148.08 Thousand USD | 0.0% |
| 2008 | -28.49 Million USD | -101003.38% |
| 2007 | -28.18 Thousand USD | -223.05% |
| 2006 | -8725.00 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -5.48 Million USD | -0.2% |
| 2024 Q2 | -1.48 Million USD | 70.4% |
| 2023 Q4 | -5.46 Million USD | -785.95% |
| 2023 FY | - USD | -143.92% |
| 2023 Q1 | -290.88 Thousand USD | -19.49% |
| 2023 Q2 | -292.1 Thousand USD | -0.42% |
| 2023 Q3 | -616.6 Thousand USD | -111.09% |
| 2022 FY | - USD | 50.72% |
| 2022 Q4 | -243.45 Thousand USD | 38.93% |
| 2022 Q2 | -1.05 Million USD | -15.56% |
| 2022 Q3 | -398.63 Thousand USD | 62.1% |
| 2022 Q1 | -910.27 Thousand USD | -22.0% |
| 2021 Q3 | -1.26 Million USD | 50.26% |
| 2021 FY | - USD | -207.08% |
| 2021 Q4 | -746.1 Thousand USD | 40.84% |
| 2021 Q1 | -610.82 Thousand USD | 73.06% |
| 2021 Q2 | -2.53 Million USD | -315.07% |
| 2020 Q4 | -2.26 Million USD | -1518.17% |
| 2020 Q2 | -509.86 Thousand USD | -254.83% |
| 2020 Q1 | 329.31 Thousand USD | 298.64% |
| 2020 Q3 | 159.87 Thousand USD | 131.36% |
| 2020 FY | - USD | -354.06% |
| 2019 FY | - USD | 170.88% |
| 2019 Q4 | 82.61 Thousand USD | -63.61% |
| 2019 Q2 | 97.3 Thousand USD | -51.77% |
| 2019 Q1 | 201.76 Thousand USD | 31044.79% |
| 2019 Q3 | 227.03 Thousand USD | 133.34% |
| 2018 Q2 | 31.44 Thousand USD | -68.15% |
| 2018 Q1 | 98.72 Thousand USD | -80.08% |
| 2018 Q4 | -652.00 USD | -100.57% |
| 2018 Q3 | 114.32 Thousand USD | 263.57% |
| 2018 FY | - USD | -66.62% |
| 2017 Q3 | 89.61 Thousand USD | 83.7% |
| 2017 FY | - USD | 174.23% |
| 2017 Q4 | 495.58 Thousand USD | 453.01% |
| 2017 Q2 | 48.78 Thousand USD | -65.51% |
| 2017 Q1 | 141.45 Thousand USD | -87.49% |
| 2016 Q2 | -1.01 Million USD | -227.17% |
| 2016 FY | - USD | -0.08% |
| 2016 Q3 | -791.9 Thousand USD | 21.86% |
| 2016 Q1 | -309.74 Thousand USD | 29.82% |
| 2016 Q4 | 1.13 Million USD | 242.82% |
| 2015 Q3 | -75.16 Thousand USD | -197.69% |
| 2015 FY | - USD | 31.08% |
| 2015 Q1 | -441.45 Thousand USD | -1.27% |
| 2015 Q2 | -25.24 Thousand USD | 94.28% |
| 2015 Q4 | -441.38 Thousand USD | -487.25% |
| 2014 Q2 | -298.83 Thousand USD | 12.96% |
| 2014 Q3 | -348.62 Thousand USD | -16.66% |
| 2014 Q1 | -343.31 Thousand USD | 76.03% |
| 2014 Q4 | -435.89 Thousand USD | -25.03% |
| 2014 FY | - USD | 31.41% |
| 2013 FY | - USD | -1304.58% |
| 2013 Q3 | -281.86 Thousand USD | -53.24% |
| 2013 Q1 | -183.23 Thousand USD | 0.0% |
| 2013 Q2 | -183.93 Thousand USD | -0.38% |
| 2013 Q4 | -1.43 Million USD | -408.05% |
| 2012 FY | - USD | 0.0% |
| 2009 Q3 | -4531.00 USD | -73.87% |
| 2009 Q1 | -18.87 Thousand USD | 99.93% |
| 2009 Q2 | -2606.00 USD | 86.2% |
| 2008 Q4 | -28.47 Million USD | -715824.56% |
| 2008 Q2 | -6462.00 USD | 8.73% |
| 2008 Q1 | -7080.00 USD | 17.66% |
| 2008 FY | - USD | -101003.38% |
| 2008 Q3 | -3978.00 USD | 38.44% |
| 2007 Q3 | -7256.00 USD | 38.06% |
| 2007 Q2 | -11.71 Thousand USD | -1795.47% |
| 2007 Q1 | -618.00 USD | 80.56% |
| 2007 FY | - USD | -223.05% |
| 2007 Q4 | -8598.00 USD | -18.5% |
| 2006 Q3 | -1578.00 USD | 59.96% |
| 2006 FY | - USD | 0.0% |
| 2006 Q4 | -3179.00 USD | -101.46% |
| 2006 Q2 | -3941.00 USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| CannBioRx Life Sciences Corp. | -22.13 Million USD | 38.012% |
| BIMI International Medical Inc. | -15.33 Million USD | 10.548% |
| China Jo-Jo Drugstores, Inc. | 1.22 Million USD | 1218.36% |
| Harrow Health, Inc. 8.625% Senior Notes due 2026 | 9.72 Million USD | 241.114% |
| Harrow Health, Inc. 11.875% Senior Notes due 2027 | 9.72 Million USD | 241.114% |
| Leafly Holdings, Inc. | -5.73 Million USD | -139.284% |
| Leafly Holdings, Inc. | -5.73 Million USD | -139.284% |
| LifeMD, Inc. | -8.21 Million USD | -67.034% |
| LifeMD, Inc. | -8.21 Million USD | -67.034% |
| PetMed Express, Inc. | -394 Thousand USD | -3382.372% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 99.878% |